Payment overview · 2025
General Payments
$226.92
10 reported records · 9 companies
Healthcare provider profile · identity verified
Travis W Davis, MD
Allopathic & Osteopathic Physicians|Family Medicine · CLERMONT, FL · NPI 1669590477
Verified facts
What the public records show
CMS Open Payments records show Travis W Davis, MD received $226.92 in general payments during 2025 across 10 reported records.
Exact Sciences Corporation accounted for 21.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Linzess by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $48.12 | 21.2% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $40.84 | 18.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $23.38 | 10.3% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $23.27 | 10.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.08 | 9.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $20.53 | 9.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.85 | 7.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.54 | 7.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.31 | 6.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $226.92 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRICLIP Normalized: triclip |
Device | Abbott Laboratories | $40.84 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $24.20 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $23.92 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $23.38 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $23.27 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $21.08 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $21.08 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20.53 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.85 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.54 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
52 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 268 | 82 |
| Lisinopril | Lisinopril | 264 | 81 |
| Levothyroxine Sodium | Levothyroxine Sodium | 215 | 57 |
| Omeprazole | Omeprazole | 213 | 62 |
| Hydrochlorothiazide | Hydrochlorothiazide | 166 | 51 |
| Amlodipine Besylate | Amlodipine Besylate | 157 | 53 |
| Metformin Hcl | Metformin Hcl | 155 | 44 |
| Simvastatin | Simvastatin | 147 | 47 |
| Losartan Potassium | Losartan Potassium | 145 | 45 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 143 | 50 |
| Lorazepam | Lorazepam | 135 | 43 |
| Gabapentin | Gabapentin | 134 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 130 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 122 | 36 |
| Tramadol Hcl | Tramadol Hcl | 113 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 104 | 47 |
| Famotidine | Famotidine | 104 | 35 |
| Jardiance | Empagliflozin | 97 | 18 |
| Furosemide | Furosemide | 96 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 85 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 84 | 31 |
| Montelukast Sodium | Montelukast Sodium | 83 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 83 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 80 | 28 |
| Amitriptyline Hcl | Amitriptyline Hcl | 76 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 74 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 74 | 22 |
| Potassium Chloride | Potassium Chloride | 72 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 69 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 69 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 67 | 19 |
| Pregabalin | Pregabalin | 65 | 23 |
| Celecoxib | Celecoxib | 64 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 64 | 19 |
| Trulicity | Dulaglutide | 62 | 18 |
| Clonazepam | Clonazepam | 59 | 23 |
| Diazepam | Diazepam | 59 | 16 |
| Carvedilol | Carvedilol | 57 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 57 | 17 |
| Meloxicam | Meloxicam | 56 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | 15 |
| Farxiga | Dapagliflozin Propanediol | 53 | 14 |
| Alendronate Sodium | Alendronate Sodium | 52 | 13 |
| Alprazolam | Alprazolam | 52 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 52 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 52 | 13 |
| Metformin Hcl Er | Metformin Hcl | 52 | 18 |
| Ozempic | Semaglutide | 52 | 12 |
| Trazodone Hcl | Trazodone Hcl | 51 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 45 | 13 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | suppressed |
| Allopurinol | Allopurinol | 43 | 13 |
| Glipizide Er | Glipizide | 41 | 14 |
| Mounjaro | Tirzepatide | 38 | suppressed |
| Rybelsus | Semaglutide | 37 | suppressed |
| Glipizide | Glipizide | 35 | suppressed |
| Topiramate | Topiramate | 35 | suppressed |
| Prednisone | Prednisone | 34 | 30 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 33 | 11 |
| Linzess | Linaclotide | 33 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | 14 |
| Risperidone | Risperidone | 32 | suppressed |
| Ezetimibe | Ezetimibe | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Eliquis | Apixaban | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Spironolactone | Spironolactone | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 19 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Gemfibrozil | Gemfibrozil | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 13 |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Premarin | Estrogens, Conjugated | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 14 |
| Fluconazole | Fluconazole | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 15 |
| Baclofen | Baclofen | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 12 |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Haloperidol | Haloperidol | 13 | suppressed |
| Humira(Cf) | Adalimumab | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $226.92 · 10 records | Exact Sciences Corporation | ACCRUFER, AREXVY, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, QULIPTA, SHINGRIX, TRICLIP, The Cologuard Plus Collection Kit, UBRELVY, Wegovy, XIFAXAN | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error